REGENERON AND NOVARTIS FORM STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE THE IL-1 TRAP IN RHEUMATOID ARTHRITIS AND OTHER INDICATIONS Novartis to Pay Regeneron $27 Million and Will Make $48 Million Equity Investment in Regeneron Novartis to Provide 100% Funding for Clinical Development and Provide Manufacturing Facility for Commercial Product Needs Companies Will Have Co-promotion Rights and Will Share Profits Equally
Tuesday, April 1, 2003 1 min read
Key Takeaway: REGENERON AND NOVARTIS FORM STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE THE IL-1 TRAP IN RHEUMATOID ARTHRITIS AND OTHER INDICATIONS Novartis to Pay Regeneron $27 Million and Will Make $48 Million Equity Investment in Regeneron Novartis to Provide 100% Funding for Clinical Development and Provide Manufacturing Facility for Commercial Product Needs Companies Will Have Co-promotion Rights and Will Share Profits Equally
Full Press Release Details
REGENERON AND NOVARTIS FORM STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE THE IL-1 TRAP IN RHEUMATOID ARTHRITIS AND OTHER INDICATIONS Novartis to Pay Regeneron $27 Million and Will Make $48 Million Equity Investment in Regeneron Novartis to Provide 100% Funding for Clinical Development and Provide Manufacturing Facility for Commercial Product Needs Companies Will Have Co-promotion Rights and Will Share Profits Equally.